showed

Analyzing Token Sale Models

Source Node:
Time Stamp: February 20, 2024 1:29 PM - Modified On: February 20, 2024 - Published By:
Source Cluster:
Republished By Plato

Note: I mention the names of various projects below only to compare and contrast their token sale mechanisms; this should NOT be taken as an endorsement or criticism of any specific project as a whole. It's entirely possible for any given project to be total trash as a whole and yet still have an awesome token sale model. The last few months have seen an increasing amount of innovation in token sale models. Two years ago, the space was simple: there were capped sales, which sold a fixed number of

Bitcoin, which goes hand in hand with AI technology, can we expect a continued bright outlook? 

Source Node:
Time Stamp: January 11, 2024 11:30 AM - Modified On: January 11, 2024 - Published By:
Source Cluster:
Republished By Plato

Due to the full-scale introduction of AI technology in 2023, America's big tech companies such as Meta, Amazon, and Twitter are threatening human jobs by laying off more than 100,000 employees a year alone. In the aftermath of this, some experts say that the pace of AI development should be slowed down to prevent further harm to human jobs, but on the other hand, most experts believe that human development should proceed together in a society that coexists with AI, rather than slowing it down. There was also an opinion

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

Source Node:
Time Stamp: December 29, 2023 3:07 AM - Modified On: December 29, 2023 - Published By:
Source Cluster:
Republished By Plato

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:21 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

CoinDesk’s Consensus 2023 Draws 15,000 Attendees from Around the Globe to Austin, Texas

Source Node:
Time Stamp: May 10, 2023 12:35 PM - Modified On: May 10, 2023 - Published By:
Source Cluster:
Republished By Plato

AUSTIN, Texas, May 10, 2023 — CoinDesk's annual event, Consensus 2023, concluded on April 28th, bringing together a diverse group of 15,000 attendees, including developers, investors, policymakers, and major brands, to tackle the most pressing challenges facing crypto and Web3 today. CoinDesk is celebrating its 10th anniversary this year and the 9th year of Consensus. As the world's largest and most influential gathering of the crypto, blockchain, and Web3 communities, Consensus 2023 was a call to action to collaborate, innovate and find solutions to drive the industry forward. “Amid a